Search - tctmd.com

Displaying 1 - 20 of 49

Sort: Relevancy | Date

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Daily News

Lp(a) Can Vary Over Time in ASCVD Patients With High Baseline Levels: OCEAN(a)-DOSE

Yael L. Maxwell

December 13, 2024

News Daily News

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Michael O'Riordan

November 07, 2024

News Daily News

PREVENT Risk Calculator Means Fewer Patients on Statins, Antihypertensives

Michael O'Riordan

August 02, 2024

News Daily News

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Michael O'Riordan

July 29, 2024

News Daily News

Think You Need a Statin? AHA’s Risk Calculator May Disagree

Michael O'Riordan

June 28, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

News Daily News

Latest Statin Risk-Benefit Analysis: More Harm Than Good?

Yael L. Maxwell

July 15, 2021

News Conference News SCAI 2021

In African-American Patients, Nontraditional Risk Factors Track With Early CAD

Michael O'Riordan

April 28, 2021

News Daily News

Rosuvastatin-Canagliflozin Combo May Be Toxic, Case Suggests

Todd Neale

August 03, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Conference News ESC 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Yael L. Maxwell

August 31, 2019

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

News Conference News SCAI 2019

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Yael L. Maxwell

June 03, 2019

News Conference News EAS 2019

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

Michael O'Riordan

May 30, 2019

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

Advertisement

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Lp(a) Can Vary Over Time in ASCVD Patients With High Baseline Levels: OCEAN(a)-DOSE

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

PREVENT Risk Calculator Means Fewer Patients on Statins, Antihypertensives

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Think You Need a Statin? AHA’s Risk Calculator May Disagree

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Latest Statin Risk-Benefit Analysis: More Harm Than Good?

In African-American Patients, Nontraditional Risk Factors Track With Early CAD

Rosuvastatin-Canagliflozin Combo May Be Toxic, Case Suggests

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content